Kallikrein-2 inhibitor, cyclic (KLK2b ht4) -1mg

Overview

The Kallikrein-2 inhibitor, cyclic (KLK2b ht4), is a refined head-to-tail cyclic peptide specifically designed to inhibit human glandular kallikrein enzyme, kallikrein-2 (KLK2). KLK2 plays a pivotal role in various physiological processes and is notably elevated in tumor tissues and serum of patients suffering from prostate cancer. By targeting this enzyme, KLK2b ht4 presents a promising approach as a potential therapy for those with prostate cancer, providing a critical biomarker for diagnostics and treatment strategies.

Key Features

• Highly stable cyclic peptide structure
• Specific inhibition of KLK2 enzyme activity
• Potential therapeutic implications for prostate cancer
• Useful in research surrounding glandular kallikrein
• Available in a 1 mg format for flexibility in applications

Specifications

FAQ

What is KLK2 and why is it important?

Kallikrein-2 (KLK2) is a serine protease that has increased expression in prostate cancer tissues and is utilized as a biomarker for diagnostics. Monitoring and inhibiting KLK2 can provide critical insights into cancer progression.

How does KLK2b ht4 work?

This cyclic peptide inhibits KLK2 activity by binding to the active site of the enzyme, effectively blocking its function. This makes it a valuable tool for research into prostate cancer therapies.

Can I use KLK2b ht4 in my research?

Absolutely! KLK2b ht4 is designed for use in research settings, particularly those focused on prostate cancer and kallikrein-related studies. It’s an excellent addition to your peptide library for exploring novel therapeutic strategies.

If you’re looking to enhance your research on KLK2 treatment strategies, consider adding KLK2b ht4 to your toolkit. Explore more peptides in our catalog to find other products that can complement your studies, like Autocamtide-2 and CREBtide. Start your journey toward impactful research with KLK2b ht4 today!

Related Products

• PKG Substrate [RKRSRAE], Glasstide

Browse more in Peptides.